Latest Tyrosine kinase receptors Stories
At ASCO 2015, University of Colorado Cancer Center reports promising clinical trial results of ONT-380 against HER2+ breast cancer Chicago, Il (PRWEB) May 30,
Phase 1 study of MM-302 will be presented in a plenary oral session CAMBRIDGE, Mass., March 26, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.
-- Novel irreversible pan-erbB inhibitor is active against patient-derived GBM xenografts overexpressing EGFR, including the disease-driving EGFRvIII mutation MENLO PARK, Calif., Dec.
Studies Using Caris Molecular Intelligence(TM) Identify Standard as well as Novel Therapeutic Options Based on Molecular Characterization of Individual Patients' Tumors IRVING, Texas,
However, Restrictions in Drug Coverage and Molecular Testing Limit Patient Access to Biomarker-Associated Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
HER3-positive circulating tumor cells home in on omentum; new target to thwart metastasis
Scientists at Cold Spring Harbor Laboratory (CSHL) today report a discovery that they hope will lead to the development of a powerful new way of treating an aggressive form of breast cancer.
Proceeds Will Advance Proprietary Biologic Product Candidates Targeting Receptor Tyrosine Kinases NEW HAVEN, Conn., March 26, 2014 /PRNewswire/ -- Kolltan Pharmaceuticals, a privately
The epidermal growth factor receptor (EGFR) is expressed in normal colonic cells and is activated by specific peptide growth factors that regulate cell proliferation, survival and differentiation.
- The parings of haberdine; also, any kind of fragments.